Replimune is laying off an additional 161 employees across Woburn and Framingham sites, following 63 prior layoffs, totaling about 60% of its workforce.1
Layoffs result from FDA's second rejection of RP1 (vusolimogene oderparepvec) on April 10, 2026, citing insufficient evidence of effectiveness despite resubmission.12
FDA reviewers determined data from trials were inadequate for approval in advanced melanoma treatment with nivolumab.1
CEO Sushil Patel expressed disappointment, criticizing FDA's process; company plans to continue operations with RP2 in trials.1
Stock plunged 64-75% post-rejection; cash reserves of $269M expected to last to Q1 2028, but financing risks rise.2
Company scaling back U.S. manufacturing to preserve capital amid regulatory uncertainty.2
Sources:
1. https://www.fiercebiotech.com/biotech/replimune-sheds-60-staff-after-fda-rejection-vows-continue-operations
2. https://www.thestreet.com/investing/stocks/replimune-stock-collapses-64-following-fda-rejection